Interim fluorodeoxyglucose positron emission tomography for early response assessment in diffuse large B cell lymphoma: where are we now?
about
Predictive Efficacy of Interim Positron Emission Tomography/Computed Tomography (PET/CT) for the Treatment of Aggressive Lymphoma18F-FDG PET/CT for early response assessment in diffuse large B-cell lymphoma: poor predictive value of international harmonization project interpretation.Assessment of chemotherapy response in non-Hodgkin lymphoma involving the neck utilizing diffusion kurtosis imaging: a preliminary studyPredictive value of interim PET/CT in DLBCL treated with R-CHOP: meta-analysisPrognostic significance of interim PET/CT based on visual, SUV-based, and MTV-based assessment in the treatment of peripheral T-cell lymphoma.Neutrophil/Lymphocyte Ratio, Lymphocyte/Monocyte Ratio, and Absolute Lymphocyte Count/Absolute Monocyte Count Prognostic Score in Diffuse Large B-Cell Lymphoma: Useful Prognostic Tools in the Rituximab Era.Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.Peripheral blood lymphocyte to monocyte ratio recovery from low levels at diagnosis after completion of first line therapy predicts good clinical outcomes in patients with diffuse large B-cell lymphoma.The Association Between Liver and Tumor [18F]FDG Uptake in Patients with Diffuse Large B Cell Lymphoma During Chemotherapy.Prognostic role of peripheral blood lymphocyte/monocyte ratio at diagnosis in diffuse large B-cell lymphoma: a meta-analysis.Whole-body diffusion-weighted magnetic resonance imaging at 3 Tesla for early assessment of treatment response in non-Hodgkin lymphoma: a pilot study.Midtreatment 18F-fluorodeoxyglucose positron-emission tomography in aggressive non-Hodgkin lymphoma.The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma.Prognostic role of neutrophil-to-lymphocyte ratio in diffuse large B cell lymphoma patients: an updated dose-response meta-analysis
P2860
Q26771059-DB7921BE-27BF-45D1-91F7-0E2B89EDDBE2Q33606294-9C1073F4-976B-4AFB-87A6-E8DFC26A285CQ33620670-22D74F61-FCCC-4B6A-B3DD-5AAB3B95D252Q35091121-D088FDFA-B434-4878-A9F7-6C12AAE1B753Q35232775-8402778D-A938-4E00-AD77-B6DF4230BA80Q36194582-6AD53C25-20FA-4E27-9A31-39486CDEF124Q37240835-B57A1AFE-77C2-4228-BD41-34A5F932194BQ37746065-016FF5AF-F73C-4558-9D33-6F5FE6C5F6F2Q38763481-71B9D5F3-463F-4072-B909-25861B9856FDQ41428549-7FA6588D-8522-4B35-B2FE-81CD650DAF6AQ41534428-31504C94-D14E-435C-ACF5-E33DCF353BB3Q51646044-02770C57-0FBB-4F51-A570-B16713BCCEB6Q53153100-42688B3A-5EF9-4774-8325-86B7A20DCF88Q58724543-1D8E2CA5-3844-4DEC-A38B-C95ED0100963
P2860
Interim fluorodeoxyglucose positron emission tomography for early response assessment in diffuse large B cell lymphoma: where are we now?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Interim fluorodeoxyglucose pos ...... ll lymphoma: where are we now?
@en
Interim fluorodeoxyglucose pos ...... ll lymphoma: where are we now?
@nl
type
label
Interim fluorodeoxyglucose pos ...... ll lymphoma: where are we now?
@en
Interim fluorodeoxyglucose pos ...... ll lymphoma: where are we now?
@nl
prefLabel
Interim fluorodeoxyglucose pos ...... ll lymphoma: where are we now?
@en
Interim fluorodeoxyglucose pos ...... ll lymphoma: where are we now?
@nl
P2860
P1433
P1476
Interim fluorodeoxyglucose pos ...... ll lymphoma: where are we now?
@en
P2093
N George Mikhaeel
P2860
P304
P356
10.3109/10428190903275610
P577
2009-12-01T00:00:00Z